This e-learning demonstrates what you need to explain to your patients requiring treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) and how to confidently communicate these messages for an optimal physician-patient interaction.

This e-learning course discusses treatment sequencing for metastatic castration resistant prostate cancer (mCRPC) patients within the changing landscape of metastatic hormone sensitive prostate cancer (mHSPC).

Recent studies of the next generation androgen receptor signalling inhibitors (ARIs) provide exciting data regarding potential future treatment options for metastatic hormone sensitive prostate cancer (mHSPC) patients. This e-learning reviews the data from recent trials and considers the quality of life and cost considerations of such treatments. The course also considers the benefit of these therapies being added to existing treatment with docetaxel and ADT.

EACCME Accreditation

COR2ED Checkpoint, made available on https://checkpoint.cor2ed.com and organized by COR2ED, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

Information on the process to convert EACCME credit to AMA credit can be found at https://www.ama-assn.org/education/ama-pra-credit-system/agreement-european-union-medical-specialties-uems.